Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know

Core Viewpoint - Acrivon Therapeutics, Inc. has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - Rising earnings estimates indicate an improvement in the company's underlying business, suggesting potential for stock price appreciation [5][8]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - Acrivon Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10]. Recent Earnings Estimate Revisions - Acrivon Therapeutics is expected to earn -$2.70 per share for the fiscal year ending December 2025, reflecting a year-over-year change of -13.5% [8]. - Over the past three months, the Zacks Consensus Estimate for Acrivon Therapeutics has increased by 5.8%, indicating positive sentiment among analysts [8].